VACCINES VS. ANTIVIRALS: THE SHIELD AND THE SWORD IN THE FIGHT AGAINST FLU
Keywords:
Long-Acting Injectables (LAIs), HIV Pharmacology, Hepatitis B (HBV), Pharmacokinetic Tail, Nanocrystal Technology, Viral Escape Mutations, Pro-drug Formulation, Subcutaneous Delivery.Abstract
As we navigate the 2025-2026 flu season, the battle against the influenza virus remains one of the most complex challenges in modern pharmacology. This review examines the two primary pillars of defense: vaccines (preventative) and antivirals (reactive). We explore the shift from quadrivalent to trivalent vaccines following the extinction of the B/Yamagata lineage, the rise of mRNA technology in flu prevention, and the refined role of endonuclease inhibitors like Baloxavir marboxil. By synthesizing clinical data and public health outcomes, this article provides a comprehensive comparison of these two distinct pharmacological strategies, ultimately arguing for a synergistic approach guided by emerging AI-driven strain prediction.
References
1. WHO Global Influenza Programme (2025). "The Extinction of B/Yamagata: Moving Toward Trivalent Vaccine Standards for the 2025-2026 Season." Weekly Epidemiological Record.
2. Moderna & Pfizer-BioNTech (2025). "Phase 3 Results of mRNA-1010 and BNT161: Efficacy and Immunogenicity in the 2024-2025 Flu Season." The New England Journal of Medicine (NEJM).
3. Hayden, F. G., et al. (2024). "Baloxavir Marboxil vs. Oseltamivir: Real-World Evidence on Viral Shedding and Transmission Reduction." The Lancet Infectious Diseases.
4. VaxSeer Collaborative (2025). "Predictive Modeling and AI-Driven Strain Selection: Closing the Gap in Vaccine Effectiveness." Science Translational Medicine.
5. CDC (2026). "Influenza Vaccine Effectiveness Report: Impact of Self-Administered Nasal Sprays on Community Immunity." Morbidity and Mortality Weekly Report (MMWR).
